This company's new cancer therapy is producing remarkable results, but the company is losing money at a frightening pace. It's been a wild roller-coaster ride for Iovance Biotherapeutics (IOVA 0.25%). In February, the stock more than doubled in price, then it fell to a 52-week low in July. The stock has since recovered and at recent prices was up 47% for the year. Can Iovance keep soaring in the years to come, or is its big gain in 2024 more likely to fizzle out? Here's a look at what to expect in the near ...